本研究旨在探討一項定制分子檢測能否在腸化生 (IM) 患者中識別出發展為胃癌風險極高的患者亞組。研究人員假設，分子檢測陽性組的異型增生及胃癌病例發生率將顯著高於分子檢測陰性組。此類檢測有望指導臨床醫生更好地管理

適應症：Stomach Neoplasm

收案條件

The subject is above 50 years old or turns 50 years old in the year of recruitment
The subject is below 76 years old in the year of recruitment
The subject is willing and able to provide signed and dated patient informed consent form indicating that they has been informed of all pertinent aspects of the study

The subject who has bleeding disorders, such as haemophilia, in whom biopsies are contraindicated.
The subject with a personal history of high-grade dysplasia or GC.
The subject with liver cirrhosis.
The subject with previous total or partial gastrectomy.
The subject with severe co-morbid illness, such as end-stage renal failure (ESRF), congestive cardiac failure (CCF), severe osteoarthritis (OA), and rheumatoid arthritis (RA) requiring long-term non-steroidal anti-inflammatory drug (NSAID) therapy.
The subject with other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may interfere with the interpretation of study results and in the judgement of the investigator would make the subject unsuitable for entry into the study.
The subject on regular anti-coagulant prophylaxis such as warfarin must be able to undergo a 5-day washout period before each gastroscopy. The subject on aspirin, ticlopidine and clopidogrel must be able to undergo a one-week washout period before each gastroscopy. The subject's physician or study co-investigator will exercise their clinical judgement to ensure subject's safety.
The subject is unwilling or unable to provide signed informed consent.

收案條件維持 ClinicalTrials.gov 原始英文登錄資料，實際收案資格以研究團隊的正式評估與受試者同意書為準。資料來源：ClinicalTrials.gov，每兩週自動更新，最後同步：2026年10月8日。

用於高風險腸化生患者風險分層的分子檢測驗證（GCEP2 研究）